RT Book, Section A1 Bhutani, Vinod K. A2 Stevenson, David K. A2 Cohen, Ronald S. A2 Sunshine, Philip SR Print(0) ID 1109798893 T1 Management of Unconjugated Hyperbilirubinemia T2 Neonatology: Clinical Practice and Procedures YR 2015 FD 2015 PB McGraw-Hill Education PP New York, NY SN 9780071763769 LK accesspediatrics.mhmedical.com/content.aspx?aid=1109798893 RD 2024/03/28 AB Reduction of elevated or increasing unconjugated (indirect) bilirubin levels, measured as total plasma bilirubin (TB) or transcutaneous bilirubin (TcB), is key to the prevention of bilirubin toxicity. Preterm and sick infants are at increased risk for hyperbilirubinemia and its sequelae. Factors that place these populations at risk for hyperbilirubinemia include impaired bilirubin-albumin binding, decreased enteral intake, and decreased gastrointestinal activity, resulting in increased enterohepatic circulation. As a result of biological conditions such as vulnerability of the blood-brain barrier, asphyxia, acidosis, and hypoalbuminemia, neurotoxicity may occur at lower bilirubin levels than for term and healthy infants.